Quick Overview of Incyte

By Emilio Sanchez • Wednesday, December 13 16:36 • Permanent Link

Shares of Biotechnology company Incyte jumped 3.8% today. With many investors piling into INCY without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:

Incyte has moved -25.2% over the last year, and the S&P 500 logged a change of 16.2%
INCY has an average analyst rating of buy and is -14.16% away from its mean target price of $74.78 per share
Its trailing earnings per share (EPS) is $1.88
Incyte has a trailing 12 month Price to Earnings (P/E) ratio of 34.1 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $4.5 and its forward P/E ratio is 14.3
The company has a Price to Book (P/B) ratio of 2.92 in contrast to the S&P 500's average ratio of 2.95
Incyte is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
INCY has reported YOY quarterly earnings growth of 52.0% and gross profit margins of 0.5%
The company has a free cash flow of $646.06 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.